Daily Cardiology Research Analysis
Analyzed 64 papers and selected 3 impactful papers.
Summary
Analyzed 64 papers and selected 3 impactful articles.
Selected Articles
1. The Society of Thoracic Surgeons/ World Society for Pediatric and Congenital Heart Surgery/ European Congenital Heart Surgeons Association 2026 Clinical Practice Guidelines on Indications and Timing of Pulmonary Valve Replacement in Repaired Tetralogy of Fallot.
This multi-society guideline updates indications and optimal timing for pulmonary valve replacement after repaired Tetralogy of Fallot, emphasizing symptoms, right ventricular volumes (in adults), and pre-procedural invasive electrophysiology assessment. It integrates recent advances in imaging, exercise testing, and transcatheter valve replacement and reinforces multidisciplinary long-term surveillance.
Impact: As an evidence-based, multi-society clinical practice guideline, it is poised to standardize care and influence decision-making for a large and growing population of patients with repaired Tetralogy of Fallot.
Clinical Implications: Provides clear, contemporary criteria to trigger evaluation and timing for pulmonary valve replacement, incorporating advanced imaging metrics, exercise capacity, and electrophysiology. It supports appropriate selection between surgical and transcatheter approaches and underscores the need for multidisciplinary follow-up.
Key Findings
- Emphasizes symptoms (children and adults) and right ventricular volumes (adults) when determining timing for pulmonary valve replacement.
- Recommends consideration of invasive electrophysiology study prior to valve replacement in adults.
- Integrates advances in imaging, exercise testing, and transcatheter pulmonary valve replacement from the past 5 years.
- Reinforces multidisciplinary team assessment, treatment planning, and long-term surveillance.
Methodological Strengths
- Multi-society consensus development based on comprehensive, up-to-date evidence.
- Clear articulation of practice-relevant parameters (symptoms, RV volumes, EP testing) and modalities (surgical vs transcatheter).
Limitations
- Guideline recommendations inherently depend on the quality and consistency of underlying studies; some areas remain supported by expert opinion.
- Part 1 of a three-part series; comprehensive implementation details are distributed across companion documents.
Future Directions: Prospective validation of specific imaging/volume thresholds, the impact of pre-PVR invasive EP testing on outcomes, and comparative effectiveness of surgical versus transcatheter PVR across age groups.
The Society of Thoracic Surgeons/ World Society for Pediatric and Congenital Heart Surgery/ European Congenital Heart Surgeons Association 2026 Clinical Practice Guidelines on Indications and Timing of Pulmonary Valve Replacement in Repaired Tetralogy of Fallot incorporate the most recent evidence for pulmonary valve replacement in this growing population. New evidence related to advanced imaging, electrophysiology testing, exercise testing, and transcatheter pulmonary valve replacement has emerged in the last 5 years. Compared to existing guidelines, the current upda
2. Relative apical sparing of left ventricular longitudinal strain for the diagnosis of cardiac amyloidosis: a systematic review and meta-analysis.
Across 41 studies, RELAPS yielded an AUC of 0.818 with good specificity (83.1%) but modest sensitivity (65.9%) for cardiac amyloidosis. Performance varied by analysis software, with notably lower sensitivity using TomTec compared to GE EchoPAC, underscoring the need for standardization and prespecified cut-offs.
Impact: Defines realistic diagnostic expectations for RELAPS and identifies software-related variability, informing clinical adoption and protocol standardization in suspected cardiac amyloidosis.
Clinical Implications: RELAPS can serve as a supportive echocardiographic marker with good specificity but should not be used in isolation given modest sensitivity. Clinicians should consider software-specific performance and pair RELAPS with nuclear imaging, biomarkers, and, when needed, biopsy.
Key Findings
- Pooled AUC-ROC 0.818 with sensitivity 65.9% and specificity 83.1% for cardiac amyloidosis diagnosis using RELAPS.
- Subtype analyses showed similar performance for AL-CA and ATTR-CA without significant differences.
- Software differences were substantial: TomTec exhibited significantly lower sensitivity than GE EchoPAC, despite similar specificity.
- Standardized measurement protocols and prespecified thresholds are needed to optimize clinical performance.
Methodological Strengths
- Comprehensive search with bivariate random-effects modeling suited to diagnostic accuracy synthesis.
- Robust subgroup analyses by amyloid subtype and echocardiography software, plus meta-regression.
Limitations
- Heterogeneity in thresholds and acquisition/analysis protocols across studies may bias pooled estimates.
- Sensitivity remains modest, limiting utility as a stand-alone diagnostic tool.
Future Directions: Prospective, software-harmonized studies with prespecified RELAPS thresholds; integration of RELAPS into multimodal diagnostic algorithms and decision pathways.
BACKGROUND: Cardiac amyloidosis (CA) is underdiagnosed due to non-specific clinical and echocardiographic features. This systematic review and meta-analysis evaluated the diagnostic accuracy of the left ventricular relative apical sparing (RELAPS) pattern on speckle-tracking echocardiography. METHODS: A literature search of PubMed, Scopus and Cochrane was conducted through August 2025. RELAPS was defined as the average apical longitudinal strain divided by the sum of average basal and average middle left ventricular longitudinal strains. Diagnostic accuracy was assessed using a bivariate r
3. CHANGES IN HYPERTENSION PREVALENCE AND CONTROL IN CANADA AFTER THE COVID-19 PANDEMIC: INSIGHTS FROM THE CANADIAN HEALTH MEASURES SURVEY CYCLE 7.
In nationally representative CHMS data, hypertension prevalence rose to 27.7% in 2022–2024 from 22.0% in 2018–2019, with the largest relative increase among adults aged 20–39 years. The proportion treated and controlled declined by 13 absolute percentage points, with lower control in younger adults and women.
Impact: This large, population-representative analysis quantifies post-pandemic deterioration in hypertension metrics, identifying high-risk demographics and informing urgent public health and clinical responses.
Clinical Implications: Prioritize blood pressure screening and follow-up in younger adults and women, expand access to team-based care and home BP monitoring, and reinforce adherence and intensification strategies to reverse declining control rates.
Key Findings
- Hypertension prevalence increased to 27.7% in 2022–2024 versus 22.0% in 2018–2019 (p=0.03).
- Largest relative increase in adults aged 20–39 years (2.6% to 8.0%; +207.7%, p=0.007).
- Treated-and-controlled hypertension declined from 55.7% to 42.7% (p=0.007), with lower control in adults <60 years and in women.
Methodological Strengths
- Nationally representative, repeated cross-sectional survey across seven cycles with standardized measurements.
- Direct comparison of pre- and post-pandemic periods with stratified demographic analyses.
Limitations
- Observational survey design precludes causal inference regarding pandemic-related drivers.
- Potential variability in measurement contexts and unmeasured confounders across cycles.
Future Directions: Identify determinants of deteriorating control, test targeted interventions (e.g., digital/home BP monitoring, pharmacy-led titration), and evaluate downstream cardiovascular outcomes.
BACKGROUND: The impact of the COVID-19 pandemic on hypertension prevalence and control in Canada is unknown despite pandemic-associated changes in lifestyle behaviours, socioeconomic factors, and availability of medical care. METHODS: We compared data for non-pregnant adult participants from the 7 cycles of the nationally representative Canadian Health Measures Survey (CHMS) conducted between 2007-2009 and 2022-2024, including questionnaires and physical measurements. RESULTS: The prevalence of hypertension in CHMS adult participants remained relatively stable between 2007-2009 (20.3%,